The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical ... cancer, with additional studies to be conducted in other ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Persistent human papillomavirus (HPV) infection causes almost all cervical cancers. Cervical cancer screening is recommended ...

In fact, 25 percent of cervical cancer diagnoses occur in women over the age of 65, and cervical cancers diagnosed in this ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Indigenously developed (Human papillomavirus) HPV test kits for cervical cancer screening were launched on Wednesday (April 23, 2025). The test kits have been developed under the Department of ...

Denmark is working towards eliminating cervical cancer by 2040. The Danish Cancer Society announced this initiative. A national HPV vaccination campaign and screening program are underway.

The study titled 'Validation of Indigenous Human Papillomavirus Tests for Cervical Cancer Screening in India (i-HPV)' validated indigenously developed, rapid, point-of-care, RTPCR-based HPV ...

CERVICAL cancer is the fourth most common cancer in Jamaica, and the second leading cause of cancer-related deaths among Jamaican women. But it is considered a preventable disease, and ...